Rising cost pressures in the biopharma industry and the demand for biopharmaceutical companies to diversify their biologics portfolio require them to manufacture in smaller and more flexible plants. New high-density cell culture processes, such as concentrated perfusion, present suitable solutions to adapt to these new manufacturing conditions and to facilitate a shift toward single-use technologies.
Perfusion processing relies on the constant addition of fresh medium and the removal of spent medium from an operating bioreactor. The next generation of perfusion processes might require an increased medium depth; this is partly because of low perfusion rates of 1-2 reactor volumes per day, which sometimes are even smaller than that.
In this webinar we will discuss:
Dr. Jochen B. Sieck
Head of Laboratory Cell Culture
Pharmaceutical and biopharmaceutical manufacturing
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.